Cover Image
Market Research Report

Artificial Organs

Published by Global Industry Analysts, Inc. Product code 236739
Published Content info 201 Pages
Delivery time: 1-2 business days
Price
Back to Top
Artificial Organs
Published: May 1, 2019 Content info: 201 Pages
Description

This report analyzes the worldwide markets for Artificial Organs in US$ Million by the following Product Segments: Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

ABBOTT
Abiomed, Inc.
Asahi Kasei Medical Co., Ltd.
Baxter International, Inc.
F.Hoffmann-La Roche Ltd.
Fresenius Medical Care AG & Co. KGaA

Table of Contents
Product Code: MCP-1126

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
  • Artificial Organs
    • Artificial Heart
    • Artificial Kidneys
    • Artificial Liver
    • Artificial Pancreas
    • Artificial Lungs

2. INDUSTRY OVERVIEW

  • Artificial Organs Revolutionize Medical Industry
  • Growth Drivers
  • Growth Inhibitors
  • Artificial Organs Poised to Witness Significant Demand
  • The United States - A Dominant Force in the Artificial Organs Market
  • Artificial Kidneys Garner a Larger Pie in the Artificial Organs Market
  • Demand and Supply Imbalance
    • Table 1: Total Number of Donors, Transplants, and Waiting List in the US: 2001-2017 (includes corresponding Graph/Chart)
    • Table 2: Total Number of People on the Waiting List for Organ Transplantation in the US by Type: 2018 (includes corresponding Graph/Chart)
  • Competitive Scenario
  • Technological Advancements Spearheading Growth

3. ANALYSIS BY SEGMENT

  • Artificial Heart
  • Medical Community Poised to Embrace Artificial Heart
  • Ventricular Assist Devices
    • Select Ventricular Assist Devices
  • Artificial Mechanical Heart Valves Come of Age
  • Artificial Kidney
  • Kidney Failure: A Major Concern
  • Artificial Kidney or Dialyzers Market
  • Major Initiatives in the Artificial Kidney Space
    • The Kidney Project
    • Current Status of the Kidney Project
      • Artificial Kidney Likely to Begin Human Trials by 2019
    • Wearable Artificial Kidney May be Boon to Dialysis Patients
  • Artificial Liver
  • Bioartificial Liver Innovation Shows Potential to Avoid Transplants
  • Types of Liver Support Devices
  • Artificial Pancreas
  • Artificial Pancreas Device System Market Presents Lucrative Opportunities
  • Market Overview
  • Scientific Community Inches towards Artificial Pancreas System
  • Competition and Key Developments in Artificial Pancreas Space
  • Bionic Pancreas System
  • Types of Artificial Pancreas Delivery Systems and FDA's Efforts for their Development
  • Researchers Develop Improvised Artificial Lungs Prototype with Vasculature
  • Crucial Artificial Lung Trial Enrolls Record Number of Patients
  • Lightweight and Portable Artificial Lung Innovations

4. MARKET TRENDS AND ISSUES

  • Increasing Incidence of Cardiovascular Disease Drive the Market for Artificial Heart and VAD
    • Table 3: Prevalence of Heart Failure in Select Countries
  • Higher Development Costs and Lengthy Regulatory Process - Stumbling Blocks for Product Commercialization
  • Lack of Requisite Expertise - Hindering Implantation Process
  • Xenotransplantation - Other Alternative to Donor Organ Shortage
  • Artificial Organs from Cloned Animal Cells - A Promising Trend
  • Immunosuppressants Hold Promise in Artificial Organs Market
  • Move towards Smaller Implantable Devices
  • Barriers to Entry Significantly High in Dialyzers Market
  • Reuse of Dialyzers - A Major Issue in Dialysis Industry
  • Poor Reimbursement Environment Stymies Innovation
  • Product Recalls - A Major Blow to the Manufacturers
  • Higher Cost of Artificial Organs Hampers Broader Adoption
  • Major Issues Related to Artificial Organs
  • Financial
  • Legal
  • Ethical
  • Social

5. MACRO FACTORS IMPACTING THE ARTIFICIAL ORGANS MARKET

  • Aging Population: A Strong Growth Driver
  • Global Aging Population Statistics - Opportunity Indicators
    • Table 4: Global Population Statistics for 65+ Age Group (Male & Female) for Major Countries/ Regions (mid-2016) (includes corresponding Graph/Chart)
    • Table 5: Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart)
  • Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Kidney Dialysis Treatment
    • Table 6: Increasing Number of ESRD Patients Worldwide: 2015-2024 (includes corresponding Graph/Chart)
  • Dialysis Market to Stage Steady Growth Amid Rising Prevalence of Kidney Diseases
    • Table 7: Global Population of ESRD Patients Undergoing Treatment by Type of Modality (2010, 2015 & 2020): Percentage Breakdown of Patients Undergoing Dialysis Therapy, and Kidney Transplantation (includes corresponding Graph/Chart)
  • Distribution of Dialysis Patients by Modality
    • Table 8: Global Population of ESRD Patients Undergoing Therapy by Type of Treatment (2016): Percentage Breakdown of Patients Receiving Hemodialysis, Kidney Transplants, and Peritoneal Dialysis (includes corresponding Graph/Chart)
    • Table 9: Global Dialysis Patient Population Distribution by Modality for Select Countries (2016): Percentage Breakdown of Hemodialysis (HD) and Peritoneal Dialysis (PD) Patients for US, China, Japan, Brazil, Mexico, Germany, India, Taiwan, Turkey, Thailand, Korea, Italy, France, Egypt and Malaysia (includes corresponding Graph/Chart)
  • Developed Markets Maintain Lead, Emerging Markets to Dictate Momentum
    • Table 10: Global Dialysis Patient Population by Geographic Region/Country (2017E & 2024P): Percentage Breakdown of Patient Population for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World (includes corresponding Graph/Chart)
  • Rising Incidence of Diabetes: Opportunity Indicator for Artificial Pancreas
    • Table 11: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 (includes corresponding Graph/Chart)
    • Table 12: Global Prevalence (%) of Diabetes in Adults (20-79) by Region for the Years 2017 and 2045 (includes corresponding Graph/Chart)
    • Table 13: Global Prevalence of Diabetes - Number of Adults Diagnosed with Diabetes (in Million) by Gender for the Year 2017 (includes corresponding Graph/Chart)
    • Table 14: Worldwide Diabetes Prevalence (%) in Adults by Age Group and Gender for the Year 2017 (includes corresponding Graph/Chart)
    • Table 15: Diabetes Prevalence in Rural and Urban Areas - Number of Adults with Diagnosed Diabetes (in Million) in Urban and Rural Areas for 2017 and 2045 (includes corresponding Graph/Chart)
    • Table 16: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2017 and 2045 (includes corresponding Graph/Chart)
    • Table 17: Proportion of Deaths on Account of Diabetes in People Aged Less than 60 Years by Region for the Year 2017 (includes corresponding Graph/Chart)
  • Growing Number of Type 1 Diabetes Cases in Children
    • Table 18: Global Prevalence of Type 1 Diabetes in Children by Region (2017) (includes corresponding Graph/Chart)
    • Table 19: Top 10 Countries for Number of Children with Type 1 Diabetes (2017) (includes corresponding Graph/Chart)

6. 3D BIOPRINTING - A GAME CHANGER FOR THE ARTIFICIAL ORGANS INDUSTRY

  • Application of 3D-Printing in the Medical Field
  • 3D Printing Revolutionizing the Medical Industry's Artificial Organ Development Segment
  • "Soft" 3D Bioprinting Eliminates Concerns of Hard Plastic-based Organ Models
  • 3D Printed Organ Models with Sensors Enable Real-time Feedback...

7. TECHNOLOGICAL ADVANCEMENTS

  • UCLA Researchers Develop Cancer-Fighting Cells
  • Production of 3D-like Artificial Organs in a Device that Works like a Cotton Candy Machine
  • Harvard Scientists Create Tissue Containing Blood Vessels
  • University of Washington Researchers Create Communicating Yeast Cells
  • Scientists Define Morphospace to Evaluate Viability of Artificial Organs

8. PRODUCT OVERVIEW

  • Categorization of Artificial Organs
    • External Artificial Organs
    • Internal or Implantable Artificial Devices
  • Artificial Heart
  • Total Artificial Heart (TAH)
  • Ventricle Assist Device (VAD)
    • Table 20: Distribution of Various Uses of VADs (includes corresponding Graph/Chart)
    • Right Ventricular Assist Systems (RVAS)
    • Left Ventricular Assist Systems (LVAS)
      • Categorization of LVAS
      • First Generation LVAS
      • Second Generation LVAS
      • Third Generation LVAS
      • Benefits of LVAS
    • Major Limitations and Complications of VADs
      • Infection
      • Internal Bleeding
      • Thrombus
      • Dependability
      • Cost
  • Natural Human Heart
  • Heart Diseases
    • Congenital Heart Disease
    • Congestive Heart Failure
  • Types of Heart Failure
    • Diastolic Heart Failure
    • Systolic Heart Failure
  • Artificial Heart - A Historical Perspective
  • Major Milestones in Artificial Heart Development
    • Jarvik-7
    • AbioCor Total Artificial Heart
    • CardioWest Temporary Total Artificial Heart
    • DuraHeart LVAS
    • HeartSaverVAD
    • VentrAssist Left Ventricular Assist Device
  • Artificial Kidney (Dialyzer)
  • Limitations of Artificial Kidney
  • Types of Dialysis
    • Hemodialysis
    • Peritoneal Dialysis
  • Advancements in Artificial Kidney Technology
  • Bioartificial Kidneys
    • Limitations of Bioartificial Kidneys
  • Hindrances to Develop Implantable Artificial Kidney
  • Artificial Kidneys - A Historical Perspective
  • Artificial Liver
  • Overdose of Drugs - A Leading Cause for Liver Damage
  • Categorization of Liver Devices
    • Mechanical Systems
      • Liver Dialysis Unit(tm)
    • Bio-Artificial Systems
      • Capillary Hollow Fiber Systems
      • Direct Perfusion Systems
      • Entrapment Based Systems
      • Major BAL Devices
      • Extracorporeal Liver Assist Device (ELAD)
      • Cellular Components
      • Types of Bioreactor
      • Hybrid Artificial Liver Support System
  • History of Artificial Liver
    • Liver Assist Devices - Major Milestones
      • Nonbiological Method Introduction Time Line
      • Biological Method Introduction Time Line
  • Artificial Pancreas
  • Insulin Pumps - Historical Perspective
  • Bioartificial Pancreas
  • Nanotechnology in Artificial Pancreas
  • Artificial Lungs (Oxygenator)
  • About Human Lungs
  • Types of Artificial Lung
    • Intravenous Membrane Oxygenator
      • Hattler Respiratory Catheter
    • MC3 Pulmonary Assist Device
      • In-Series
      • In-Parallel
    • BioLung
  • Heart-Lung Bypass Machine
  • Role of Artificial Lungs during Surgery
    • Direct Contact Device
  • Indirect-Contact Type-Membrane Devices
  • Biorubber to be used in Artificial Lungs
  • History of Artificial Lungs
  • An Overview of Tissue Engineering

9. REGULATORY ENVIRONMENT

  • Regulatory Environment in the US
  • Regulatory Environment in Europe

10. COMPETITIVE LANDSCAPE

  • 10.1 Focus on Select Global Players
  • ABBOTT (USA)
  • Abiomed, Inc. (USA)
  • Asahi Kasei Medical Co., Ltd. (Japan)
  • Baxter International, Inc. (USA)
  • F.Hoffmann-La Roche Ltd. (Switzerland)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Jarvik Heart, Inc. (USA)
  • Medtronic, Inc. (USA)
  • HeartWare International, Inc. (USA)
  • Nikkiso Co., Ltd. (Japan)
  • Nipro Corporation (Japan)
  • SynCardia Systems, LLC (USA)
  • Toray Medical Co., Ltd. (Japan)
  • Xenios AG (Germany)
  • 10.2 Recent Industry Activity
  • Vital Therapies Reports the Failure of ELAD System in Phase III Trial
  • A Ten-Year-Old Becomes the Youngest Patient to Receive 50CC Temporary TAH
  • Tandem Diabetes Care Secures FDA Approval for Closed-loop Insulin System
  • ALung Registers Record Enrollment for the Pivotal Trial of Artificial Lung Technology
  • Automated Insulin Delivery and Monitoring System Receives FDA Approval for Use in Younger Pediatric Patients
  • Artificial Lung Rises Hope for Future Transplant Patients
  • Medtronic Introduces 'Artificial Pancreas' Hybrid Closed Loop System in the U.S.
  • Johnson & Johnson Exits Insulin Pump Business
  • B. Braun Introduces New Dialyzer
  • Versa Ventures Acquires Syncardia
  • Medtronic and HeartWare International Ink Merger Agreement
  • Vivonics Sells Artificial Lung Technology to Lung Biotechnology PBC
  • Insulet Corporation Enters into a Partnership and License Agreement with Mode AGC
  • Cellnovo Group Enters into a Partnership with TypeZero
  • Medtronic Launches MiniMed(TM) 640G System
  • Pandorum Develops Artificial Human Liver Tissue

11. GLOBAL MARKET PERSPECTIVE

    • Table 21: World Recent Past, Current & Future Analysis for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 22: World Historic Review for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 23: World 14-Year Perspective for Artificial Organs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current & Future Analysis for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 25: World Historic Review for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 26: World 14-Year Perspective for Artificial Organs by Product Segment - Percentage Breakdown of Dollar Sales for Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
    • Table 27: World Recent Past, Current & Future Analysis for Artificial Kidneys/ Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 28: World Historic Review for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 29: World 14-Year Perspective for Artificial Kidneys/Dialyzers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
    • Table 30: World Recent Past, Current & Future Analysis for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 31: World Historic Review for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 32: World 14-Year Perspective for Insulin Pumps (External) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

12. REGIONAL MARKET PERSPECTIVE

  • 12.1 The United States
  • A. Market Analysis
    • SynCardia's temporary Total Artificial Heart: The Only FDA Approved Artificial Heart
    • Ageing Demographics: A Major Driving Factor for Artificial Organs Market
    • Table 33: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Dialysis Patient Population- An Opportunity Indicator for Artificial Kidneys
    • Table 34: Dialysis Patient Population in the US (2015-2024) (includes corresponding Graph/Chart)
    • Table 35: US Dialysis Patient Population by Modality (2016) (includes corresponding Graph/Chart)
    • Single Use Dialyzers Gain Traction
    • Diabetes: A Key Growth Driver
    • Table 36: Diabetes and Population Statistics in North America and Caribbean Region (2017 & 2045) (includes corresponding Graph/Chart)
    • Table 37: Diabetes Statistics in the US (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed Diabetes ('000s), and Number of Diabetes-Related Deaths (in '000s)
  • B. Market Analytics
    • Table 38: The US Recent Past, Current & Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 39: The US Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • 12.2 Rest of World
  • A. Market Analysis
    • Table 40: Diabetes and Population Statistics in Europe (2017 & 2045) (includes corresponding Graph/Chart)
    • Table 41: Diabetes Statistics in Europe (2017) - Adults with Diabetes (20-79) in 1,000s, Diabetes Age-Adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed Diabetes (20-79) in 1,000s, and Diabetes Related Deaths (20-79 years) for Select Countries (includes corresponding Graph/Chart)
    • Table 42: Diabetes Statistics in Western Pacific (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed diabetes ('000s) and Number of Diabetes-Related Deaths (in '000s) for Select Countries (includes corresponding Graph/Chart)
    • Table 43: Diabetes Statistics in South East Asia (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed Diabetes ('000s) and Number of Diabetes-Related Deaths (in '000s) for Select Countries (includes corresponding Graph/Chart)
    • Table 44: Diabetes Statistics in South & Central America (2017) - Number of Adults with Diabetes (20-79 (in 000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed Diabetes) ('000s), and Number of Diabetes-Related Deaths (in '000s) for Select Countries (includes corresponding Graph/Chart)
    • Table 45: Diabetes Statistics in Africa (2017) - Number of Adults (20-79) with Diabetes (in '000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed Diabetes (20-79) ('000s), and Number of Diabetes-Related Deaths (in '000s) for Select Countries (includes corresponding Graph/Chart)
    • Table 46: Diabetes Statistics in Middle East and North Africa for 2017 and 2045 (includes corresponding Graph/Chart)
    • Table 47: Diabetes Statistics in Middle East and North Africa (2017) - Number of Adults with Diabetes (in 000s), Diabetes age-adjusted (20-79) Comparative Prevalence (%), Adults with Undiagnosed diabetes (20-79) ('000s), and Number of Diabetes-Related Deaths (in '000s) for Select Countries (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 48: Rest of World Recent Past, Current & Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 49: Rest of World Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

13. COMPANY PROFILES

  • Total Companies Profiled: 42 (including Divisions/Subsidiaries - 47) The United States (20) Japan (8) Europe (13) - France (2) - Germany (4) - The United Kingdom (2) - Rest of Europe (5) Asia-Pacific (Excluding Japan) (4) Middle East (2) ARTIFICIAL ORGANS MCP-1126 CONTENTS
Back to Top